

## DAFTAR PUSTAKA

- Aerts, B. R. J., Kock, M. C. J. M., Kofflard, M. J. M., & Plaiser, P. W. (2013) Cardiac metastasis of malignant melanoma: A case report. *Neth Heart J*; 22: 39-41.
- Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S. Noonan, D. M. (2010) Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. *J Natl Cancer Inst*; 102(1): 14-25.
- Ali, O. M., Sheheryar, Q., & Nabeel, Y. (2014) A Case of Primary Cardiac Sarcoma. *J Clin Trial Cardiol*; 1(1), 1-4.
- Amad, H. & Leong, H. (2006) *Primary Cardiac Tumours*. Cardiology Rounds XI(9).
- Ana, G., Krleža, J. L., Obuljen, J., Žižić, V., Stepan-Giljević, J. & Kapitanović, S. (2012). NT-proBNP in anthracycline-induced cardiotoxicity in children. *2nd European Joint Congress of EFLM and UEMS*.
- Apple, F.S., Voss, E., Lund, L., Preese, L., Berger, G.R., Henry, T.D. (1995) Cardiac troponin, CK-MB and myoglobin for the early detection of acute myocardial infarction and monitoring of reperfusion following thrombolytic therapy. *Clinica Chimica Acta*; 237: 59-66.
- Badan Penelitian Kementrian Kesehatan RI (2013) *Riset Kesehatan Dasar 2013*, Jakarta: Kementrian Kesehatan RI.
- Barrett-Lee, P., Bokemeyer, C., Gascon, P., Nortier, J., Schneider, M., Schrijvers, D. & Van Belle, S. (2005) Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. *The oncologist*, 10(9): 743-757.
- Beasley, M., Driver, D., & Dobbs, H. J. (2005) *Complications of radiotherapy: improving the therapeutic index*. *Int Cancer Imaging*; 5: 78-84.
- Berardi, R., Caramanti, M., Savini, A., Chiorrini, S., Pierantoni, C., Onofri, A., Ballatore, Z., De Lisa, M., Mazzanti, P. & Cascinu, S. (2013) State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review. *Crit Rev Oncol Hematol*; 88(1):75-86.
- Bodai BI, Tusio P. (2015) Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. *Perm J*;19:48-79.
- Boerma, M. (2012) Experimental radiation-induced heart disease: past, present, and future. *Radiat Res*; 178(1): 1-6.

- Bowles, N. & Towbin, J. (2003) Childhood Myocarditis and Dilated Cardiomyopathy. *In: Cooper, L. (ed.) Myocarditis: from bench to bedside.* New Jersey: Humana Press: 559-87.
- Bowles, E.J.A., Wellman, R., Feigelson, R.S., Onitilo, A.A., Freedman, A.N., Delate, T., Allen, L.A., Nekhlyudov, L., Goddard, K.A.B., Davis, R.L., Habel, L.A., Yood, M.U., McCarty, C., Magid, D.J., Wagner, E.H.(2012) Risk of Heart Failure in Breast cancer Patients After Anthracycline and trastuzumab treatment: A retrospective cohort Study. *J Natl Cancer Inst*, 104:1293–1305.
- Braña, I., Zamora, E. & Tabernero, J. (2013) *Cardiotoxicity in Side Effects of Medical Cancer Therapy.* London: Springer.
- Bussani, R., De-Giorgio, F., Abbate, A., & Silvestri, F. (2007) Cardiac metastases. *J Clin Pathol*; 60: 27-34.
- Cardinale, D. & Cipolla, C. M. (2011) Assessment of cardiotoxicity with cardiac biomarkers in cancer patients. *Herz*; 36(4): 325-32.
- Cardinale, D., & Sandri, M. T. (2010) Role of biomarkers in chemotherapy-induced cardiotoxicity. *Prog Cardiovas Dis*; 53: 121-129.
- Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., Hagerty, K. L., Somerfield, M. R. & Vaughn, D. J. (2007) American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. *J Clin Oncol*; 25(25): 3991-4008.
- Chandra, A.P., Hermanto, D. H. & Waskito (2016) Peningkatan NT-proBNP dan cTn-I serum pasien limfoma Non-Hodgkin's yang menerima kemoterapi berbasis doxorubicin. *Jurnal Kedokteran Brawijaya*; 29 (2):143-148.
- Cheng, H., & Force, T. (2010) Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. *Cir Res*; 106(1): 21-34.
- Cheruvu, B., Cheruvu, P., Boyars, M. (2011) An unusual case of metastasis to the left side of the heart: A case report. *J Med Case Reports*; 5(23).
- Christenson, E. S., Jamesa, T., Agrawala, V. Parkb, B. H. (2015) Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. *Clin Biochem*; 48(0): 223-235.
- Choi, E.Y., Kwon, H.M., Yoon, Y.W., Kim, D., Kim, H.S (2004) Assessment of extent of myocardial ischemia in patients with Non-ST elevation acute coronary syndrome using serum B-Type natriuretic peptide level. *Yansei Med J*; 45:255-62.

- Collinson, P. O. (2005) *Natriuretic Peptides*. Business Briefing: European Cardiology.
- Daniels, L. B. & Maisel, A. S. (2014) Natriuretic Peptides. *J Am Col Cardiol*; 50:25.
- DeCara, J. M. (2012) *Early detection of chemotherapy-related left ventricular dysfunction*. *Curr Cardiol Rep*; 14(3): 334-341
- De Lemos, J.A., McGuire, D.K., Drazner, M.H.(2003) B-type natriuretic peptide in cardiovascular disease. *The Lancet*; 36: 316-22.
- Dent S, Liu P, Brezden-Masley C, Lenihan D. (2015) Cancer and cardiovascular disease: the complex labyrinth [serial online]. *J Oncol*.;2015:516450.
- Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray , J. J. V., Ponikowski, P., Poole-Wilson, P. A. (2008) Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*; 10: 933-989.
- Drimal, J., Zurova-Nedelcerova, J., Knelz, V., Sotnikova, R., & Navarova, J. (2006) Cardiovascular toxicity of the first line cancer chemotherapeutic agents: Doxorubicin, cyclophosphamide, streptozotocin and bevacizumab. *Neuro Endocrinol Lett*; 27: 176-179.
- Ejaz, A., Kambhampati, G., Ejaz, N., Dass, B., Lapsia, V., Arif, A., Asmar, A., Shimada, M., Alsabbagh, M., Aiyer, R. & Johnson, R. (2012) Post-operative serum uric acid and acute kidney injury. *J Nephrol*, 25(4): 497-505.
- Emdin, M., Vittorini, S., Passino, C., & Clerico, A. (2009) Old and new biomarkers of heart failure. *Eur J Heart Fail*; 11: 331-335.
- Ewer, M. S. & Ewer, S. M. (2010) Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. *Nat Rev Cardiol*; 7(10): 564-75.
- Ewer MS, Ewer SM. (2015) Cardiotoxicity of anticancer treatments [serial online]. *Nat Rev Cardiol*.;12:620.
- Folkman, J. (1971) *Tumor angiogenesis: therapeutic implications*. *NEJM*; 285: 1182-1186.
- Force T, Kolaja KL. (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. *Nat Rev Drug Discov*.;10:111-126.
- Gaggin, H.K. & Januzzi Jr, J.L. (2013) Biomarkers and diagnostics in heart failure. *Biochimica et Biophysica Acta*; 1832: 2442–2450

- Gaya, A. M., & Ashford, R. F. U. (2005) Cardiac complications of radiation therapy. *Clin Oncol*; 17: 153-159.
- Givertz, M. M. (2000) Underlying causes and survival in patients with heart failure. *NEJM*; 342(15): 1120-1122.
- Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S. & Franco, S. (2014) Heart disease and stroke statistics--2014 update: A report from the American Heart Association. *Circulation*; 129(3): e28.
- Goodman, L. S., Brunton, L. L., Gilman, A., Chabner, B., & Knollmann, B. C. (2011) *Goodman & Gilman's The pharmacological basic of Therapeutics*. New York: McGraw-Hill Medical.
- Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. (1981) Cardiotoxicity associated with highdose cyclophosphamide therapy. *Arch Intern Med*; 141: 758-763.
- Green, D. R. & Kroemer, G. (2009) Cytoplasmic functions of the tumor suppressor p53. *Nature*; 458(7242): 1127.
- Hall, C. (2004) Essential biochemistry and physiology of NT-proBNO. *Eur J Heart Fail*; 6:257-60.
- Harbeck, B., Joost, A., Lehne, W., Böhm, A., Sufke, S., Werth, S., Lehnert, H. & Haas, C. S. (2012) A hypertensive patient presenting with paraneoplastic perimyocarditis and myositis due to pheochromocytoma. *International journal of cardiology*, 160(2): e23-e24.
- Hennesy, B.T., Smith, D.L., Ram, P.T., Lu, Y. & Mills, G.B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nat Rev Drug Discov*; 4: 988-1004.
- Herrmann, J., Lerman, A., Sandhu, N.P., Villarraga, H.R., Mulvagh, S.L., Kohli, M. (2014) Evaluation and management of patients with heart disease and cancer: cardio-oncology. *Mayo Clin Proc*; 89(9): 1287–1306.
- Howlader N, Ries LAG, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. (2010). Improved estimates of cancer-specific survival rates from population-based data. *J Natl Cancer Inst*; 102:1584-1598.
- Hunt, S.A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M. & Michl, K. (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001

Guidelines for the Evaluation and Management of Heart Failure). *J Am Coll Cardiol*; 46(6): 1116-1143.

Jemal A, Ward E, Hao Y, Thun M. (2005). Trends in the leading causes of death in the United States, 1970–2002. *JAMA*.; 294:1255-1259.

Jurcut, R., Wildiers, H., Ganame, J., D’hooge, J., Paridaens, R. & Voigt, J.-U. (2008) Detection and monitoring of cardiotoxicity-what does modern cardiology offer? *Support Care Cancer*; 16:437-445.

Katalinic, D., Stem-Padovan, R., Ivanac, I., Aleric, I., Tentor, D., Nikolac, N., Santek, F., Juretic, A., & Plestina, S. (2013) Symptomatic cardiac metastases of breast cancer 27 years after mastectomy: A case report with literature review-pathophysiology of molecular mechanisms and metastatic pathways, clinical aspects, diagnostic procedures and treatment modalities. *World J Surg Oncol*; 11:14-23.

Lancellotti, P., Nkomo, V. T., Badano, L. P., Bergler-Klein, J., Bogaert, J., Davin, L., Cosyns, B., Coucke, P., Dulgheru, R. & Edvardsen, T. (2013) Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the european association of cardiovascular imaging and the american society of echocardiography. *Eur Heart J Cardiovas Imag*, 14(8): 721-740.

Kementerian Kesehatan RI. (2015) *Pusat data dan informasi: Stop kanker*. Jakarta: Kementerian Kesehatan RI.

Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S. & Clubb, F. J. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. *Nat Med*; 12(8): 908-916.

Khakoo, A. Y., Liu, P. P., Force, T., Berestein, G. L., Jones, L. W., Schneider, J., & Hill, J. (2011) Cardiotoxicity due to cancer therapy. *Tex Heart In J*; 38(3):253-256.

Kouloubinis, A., Sofroniadou, S., Panoulas, V. F., Makaritsis, K., Revela, I., Karavolias, G., Voudris, V. & Adamopoulos, S. (2015) The role of TNF- $\alpha$ , Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines. *IJC Heart & Vasculature*, 6: 85-90.

Kragelund, C., Gronning, B., Kobert, L., Hildebrandt, P. & Steffensen, R. (2005) N-terminal proB-type natriuretic peptide and longterm mortality in stable coronary heart disease. *NEJM*; 352:666-672.

Kruger, A. & Wojnowski, L. (2006) Cardiotoxicity of anthracyclines—an unsolved problem. *Deutsches Arzteblatt*; 103(37): A2393-A2397.

- L'Ecuyer, T., Sanjeev, S., Thomas, R., Novak, R., Das, L., Campbell, W., & Heide, R. V. (2006) DNA damage is an early event in doxorubicin-induced cardiac myocyte death. *Am J Physiol Heart Circ Physiol*; 291: H1273-H1280.
- Lemmens K., Segers V.F., Demolder M. & De Keulenaer G.W. (2006) Role of Neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. *J Biol Chem*; 281: 19469-19477.
- Lenihan, D.J. (2010) PREDICT Trial: Prospective Point of Care Cardiac Biomarkers to Detect Cardiotoxicity. *Cardiology and Oncology Partnership: IV Annual International Symposium*. Symposium conducted at the meeting of Cardiology and Oncology Partnership, Nashville, TN.
- Lenihan, D.J., Massey, M.R., Baysinger, K.B., Adorno, C.L., Warneke, C. L., ... Yeh, E. (2007) Superior detection of cardiotoxicity during chemotherapy using biomarkers. *J Cardiac Fail*; 13 (6).
- Lenihan, D.J., Massey, M. R., Isabel, J., Baysinger, K., Steinert, D., Fayad, L., Champion, J. C., Yusuf, S. & Yeh, E. T. (2006) Early Detection of Cardiotoxicity During Chemotherapy using Biomarkers. *J Cardiac Fail*; 12 (6):S92.
- Liphultz, S.E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D. & Colan, S. D. (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. *NEJM*; 332(26): 1738-1744.
- Liu, X., Chua, C. C., Gao, J., Chen, Z., Landy, C. L. C., Hamdy, R. & Chua, B. H. L. (2004) Pifithrin- $\alpha$  protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. *Am J Physiol Heart Circ Physiol*; 286: H933-H939.
- Marti, G., Galve, E., Huguet, J. & Soler, J.S. (2004) Cardiac metastases of malignant melanoma mimicking sick sinus syndrome. *Rev Esp Cardiol*; 57(6): 589-91
- Matoes, E., Jug, B., Blagus, R. & Zakotnik, B. (2016) A Prospective cohort study on cardiotoxicity of adjuvant trastuzumab therapy in breast cancer patients. *Sociedade Brasileira De Cardiologia*; 107 (1); 40-47.
- McMurray, J. J.V., Adamopoulos, S., Anker, S. D., Auricchio, A., Bohm, M. & Dickstein, K. (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*; 33:1787-1847.



- Meinardi, M.T., van der Graaf, W.T.A., van Veldhuisen, D.J., Gietema, J.A., de Vries, E.G.E., & Sleijfer, D.T. (1999) Detection of anthracycline-induced cardiotoxicity. *Cancer Treat Rev*; 25: 237-247.
- Mladosievicova, B., Urbanova, D., Radvanska, E., Slavkovsky, P. & Simkova, I. (2012) Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines. *J Exp Clin Cancer Res*; 31(1):86-91.
- Monsuez, J., Charniot, J., Vignat, N., & Artigo, J. (2010) Cardiac side-effect of cancer chemotherapy. *Int J Cardiol*; 144: 3-15.
- Narula, J., Haider, N., Arbustini, E., & Chandrashekar, Y. (2006) Mechanisms of disease: Apoptosis in heart failure - seeing hope in death. *Nat Rev Cardiol*; 3: 681-688.
- Neves, J. S., Leite-Moreira, A. M., Neiva-Sousa, M., Almeida-Coelho, J., Castro-Ferreira, R. & Leite-Moreira, A. F. (2015) Acute myocardial response to stretch: what we (don't) know. *Frontiers in physiology*, 6:1-11
- Özcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hübner, N., Chien, K. R., Birchmeier, C. & Garratt, A. N. (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. *Proceedings of the National Academy of Sciences*, 99(13): 8880-8885.
- Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R. & Jackisch, C. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *NEJM*, 353(16): 1659-1672.
- Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N. & Giordano, S. H. (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. *Journal of Clinical Oncology*, 25(25): 3808-3815.
- Plana, J. C. (2011) Chemotherapy and the heart. *Revista Española de Cardiología* (English Edition), 64(5): 409-415.
- Ponikowski, P., Voors, A., Anker, S., Bueno, H., Cleland, J., Coats, A., Falk, V., González-Juanatey, J., Harjola, V. & Jankowska, E. (2016) Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*, 18(8): 891-975.

- Procter M, Suter TM, de Azambuja E, et al. (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. *J Clin Oncol*. 2010;28:3422-3428.
- Prosnitz, R. G. & Marks, L. B. (2005) Radiation-induced heart disease: Vigilance is still required. *J Clin Oncol*; 23(30).
- Raikhelkar, J., Steingart, R. & Chen, C. (2011) Role of echocardiography in cancer care. *Herz*; 36(4): 333-339.
- Raizada, A., Bhandari, S., Khan, M. A., Singh, H. V., Thomas, S., Saeabhai, V., Singh, N. & Trehan, N. (2007) Brain type natriuretic peptide (BNP) -a marker of new millenium in diagnosis of congestive heart failure. *Indian J Clinl Biochem*; 22(1): 4-9.
- Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) Transcriptional control of Human p53-regulated genes. *Nat Rev Mol Cell Biol*; 9: 402-412.
- Romano, S., Fratini, S., Ricevuto, E., Procaccini, V., Stifano, G., Mancini, M., Di Mauro, M., Ficorella, C. & Penco, M. (2011) Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. *British journal of cancer*, 105(11): 1663.
- Ryberg, M., Nielsen, D., Cortese, G., Nielsen, G., Skovsgaard, T., Andersen, P. (2008). New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients. *J Natl Cancer Inst* 2008;100: 1058-1067
- Sano M, Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., Akazawa, H., Tateno, K., Kayama, Y. & Harada, M. (2007) p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. *Nature*, 446(7134): 444-448.
- Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., Cohen, V., Banchs, J., Carver, J. R. & Wiegers, S. E. (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. *Circulation: Cardiovascular Imaging*, 5(5): 596-603.
- Sawyer DB. (2013). Anthracyclines and Heart Failure. *N.Eng.J.Med* 368(12):1154-6
- Seidman, A., Hudis, C., Pierri, M. K., Shak, S., Paton, V., Ashby, M., Murphy, M., Stewart, S. J. & Keefe, D. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. *J Clin Oncol*; 20(5): 1215-1221.
- Seino, Y., Ogawa, A., Yamashita, T., Fukushima, M., Ogata, K. i., Fukumoto, H. & Takano, T. (2004) Application of NT-proBNP and BNP measurements



in cardiac care: a more discerning marker for the detection and evaluation of heart failure. *Eur J Heart Fail*; 6(3):295-300.

Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., E. Rutgers, E. (2015). Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*; 26 (Supplement 5): v8–v30, 2015

S. Zackrisson<sup>8</sup> & F. Cardoso<sup>9</sup>, on behalf of the ESMO Guidelines Committee

Shaikh, A. Y. & Shih, J. A. (2012) Chemotherapy-induced cardiotoxicity. *Curr Heart Fail Rep*; 9(2): 117-127.

Siegel RL, Miller KD, Jemal A. (2015). Cancer statistics, 2015. *CA Cancer J Clin*; 65: 5-29.

Siegel, R., Miller, K.D., Zou, Z. & Jemal, A. (2016) Cancer Statistics, 2017. *Cancer J Clin*; 67: 7-30.

Simpson, J.F., Gray R., Dressler L.G., Cobau C.D., Falkson C.I., Gilchrist K.W., Pandya K.J., Page D.L. and Robert N.J. (2000) Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. *J Clin Oncol*; 18: 2059-69.

Singal, P.K., & Iliskovic, N. (1998) *Doxorubicin-induced cardiomyopathy*. *NEJM*; 339: 900-905.

Skovgaard, D., Hasbak, P. & Kjaer, A. (2014) *BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography*. *Plos one*; 9(5):e96736.

Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J. & Pegram, M. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *NEJM*, 344(11): 783-792.

Stachowiak<sup>1</sup>, P., Kornacewicz-Jach<sup>1</sup>, Z., Jach, K.S. & Safranow, K. (2014). Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy. *Arch Med Sci*; 10(5): 1007–1018.

StataCorp (2015) *STATA- Statistics Data Analysis*. College Station, Texas:StataCorp

Steinherz, L. J., Steinherz, P. G., Tan, C. T., Heller, G. & Murphy, M. L. (1991). Cardiac toxicity 4 to 20 years after completing anthracycline therapy. *JAMA*; 266: 1672-1677.

- Suyatno & Pasaribu E.T. (2014) *Kanker Payudara. Dalam: Bedah Onkologi Diagnosis dan Terapi Edisi 2*. Jakarta: Sagung Seto: 39-86
- Suzanna, E., Sirait, T., Rahayu, P. S., Shalmont, G., Anwar, E., Andalusia, R. & Panigoro, S. S. (2012) Suplemen: Registrasi Kanker Berbasis Rumah Sakit di Rumah Sakit Kanker Dharmais Pusat Kanker Nasional, 1993-2007. *Indonesian Journal of Cancer*, 6.
- Swain, S.M., Whaley, F.S. & Ewer, M.S. (2003) Congestive heart failure in patients treated with doxorubicin; a retrospective analysis of three trials. *Cancer*; 97: 2869-2879.
- Tan, C.H., Chao, T.-T., Liu, J.-C., Lin, C.-H., Huang, Y.-S., Chang, C.-M., Lin, H.-Y., Su, Y.-C., Chen, Y.-L. & Lee, C.-C. (2016) Breast cancer therapy and age difference in cardiovascular disease risks: A population-based cohort study in Taiwan. *Taiwanese J Obstetr Gynecol*, 55(1): 98-103.
- Thawabi, M., Shaaban, H., Jmeian, A., & Shamoon, F. (2014) Sick sinus syndrome as the initial manifestation of cardiac metastasis in squamous cell lung cancer: A Case Report. *J Cardiovas Dis Res*; 5(2).
- Tian, S., Hirshfield, K. M., Jabbour, S. K., Toppmeyer, D., Haffty, B. G., Khan, A. J. & Goyal, S. (2014) Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. *Frontiers in oncology* 4.
- Trent, J. C., Patel, S. S., Zhang, J., Araujo, D. M., Plana, J. C., Lenihan, D. J., Fan, D., Patel, S. R., Benjamin, R. S., & Khakoo, A. Y. (2010) Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. *Cancer*; 116(1):184- 92.
- Truong, J., Yan, A. T., Cramarossa, G. & Chan, K. K. (2014) Chemotherapy-induced cardiotoxicity: Detection, prevention, and management. *Can J Cardiol*; 30(8): 869-878.
- U.S. *Breast Cancer Statistics*. [http://www.breastcancer.org/symptoms/understand\\_bc/statistics](http://www.breastcancer.org/symptoms/understand_bc/statistics)
- Weber, M., Hamm, C. (2006). Role of B-Type Natriuretic Peptide (BNP) and NT-ProBNP in Clinical Routine. *Heart*;92:843–849. doi: 10.1136/hrt.2005.071233
- Wells, Q. S. & Lenihan, D. J. (2010) Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected? *Prog Cardiovasc Dis* 53(2): 140-8.
- Wieshammer, S., Dreyhaupt, J., Müller, D., Momm, F. & Jakob, A. (2016) Limitations of N-terminal pro-B-type natriuretic peptide in the diagnosis

of heart disease among cancer patients who present with cardiac or pulmonary symptoms. *Oncology*, 90(3): 143-150.

Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A. & Ewer, M. S. (2004) Cardiovascular complications of cancer therapy diagnosis, pathogenesis, and management. *Circulation*; 109:3122-3131.

Yildirim, A., Tunaoglu, F. S., Kanburoglu, K. & Pinarli, F. G. (2013) The utility of NT- proBNP and various echocardiographic methods in the determination of doxorubicin induced subclinical late cardiotoxicity. *Kardiologia Polska (Polish Heart Journal)*, 71(1): 40-46.

Yusuf, S., W., Sami, S., & Daher, I. N. (2011) *Radiation-induced heart disease: a clinical update. Cardiol Res Prac*; 2011:1-9.

Zidan, A., Sherief, L. M., El-sheikh, A., Saleh, S. H., Shahbah, D. A., Kamal, N. M., Sherbiny, H. S. & Ahmad, H. (2015) NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors. *Disease markers*, 2015.